Discussion: The high occurrence of both
K103N and
V106M could be a reflection of the wide use of EFV and NVP as part of the first line therapy.
Discussion: The use of nevirapine monotherapy could have potentially impacted on the observed level of
NNRTI mutations particularly
K103N.